MX2014008247A - Calmangafodipir, una nueva entidad quimica, y otros complejos de metal mezclados, metodos de preparacion, composiciones y metodos de tratamiento. - Google Patents
Calmangafodipir, una nueva entidad quimica, y otros complejos de metal mezclados, metodos de preparacion, composiciones y metodos de tratamiento.Info
- Publication number
- MX2014008247A MX2014008247A MX2014008247A MX2014008247A MX2014008247A MX 2014008247 A MX2014008247 A MX 2014008247A MX 2014008247 A MX2014008247 A MX 2014008247A MX 2014008247 A MX2014008247 A MX 2014008247A MX 2014008247 A MX2014008247 A MX 2014008247A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- treatment
- mixed metal
- calmangafodipir
- compositions
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 229910052751 metal Inorganic materials 0.000 title abstract 2
- 239000002184 metal Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 229940127285 new chemical entity Drugs 0.000 title 1
- QAOJLUYEMFXJGX-UHFFFAOYSA-D tetracalcium [4-[[carboxymethyl-[2-[carboxymethyl-[[3-hydroxy-5-[[hydroxy(oxido)phosphoryl]oxymethyl]-2-methylpyridin-4-yl]methyl]amino]ethyl]amino]methyl]-5-hydroxy-6-methylpyridin-3-yl]methyl hydrogen phosphate manganese(2+) Chemical compound [Ca++].[Ca++].[Ca++].[Ca++].[Mn++].Cc1ncc(COP(O)([O-])=O)c(CN(CCN(CC(O)=O)Cc2c(COP(O)([O-])=O)cnc(C)c2O)CC(O)=O)c1O.Cc1ncc(COP(O)([O-])=O)c(CN(CCN(CC(O)=O)Cc2c(COP(O)([O-])=O)cnc(C)c2O)CC(O)=O)c1O.Cc1ncc(COP(O)([O-])=O)c(CN(CCN(CC(O)=O)Cc2c(COP(O)([O-])=O)cnc(C)c2O)CC(O)=O)c1O.Cc1ncc(COP(O)([O-])=O)c(CN(CCN(CC(O)=O)Cc2c(COP(O)([O-])=O)cnc(C)c2O)CC(O)=O)c1O.Cc1ncc(COP(O)([O-])=O)c(CN(CCN(CC(O)=O)Cc2c(COP(O)([O-])=O)cnc(C)c2O)CC(O)=O)c1O QAOJLUYEMFXJGX-UHFFFAOYSA-D 0.000 title 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000004696 coordination complex Chemical class 0.000 abstract 2
- 230000001575 pathological effect Effects 0.000 abstract 2
- 229910052723 transition metal Inorganic materials 0.000 abstract 2
- 150000003624 transition metals Chemical class 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 238000002425 crystallisation Methods 0.000 abstract 1
- 230000008025 crystallization Effects 0.000 abstract 1
- 150000002739 metals Chemical class 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F19/00—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00
- C07F19/005—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00 without metal-C linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
- C07F13/005—Compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F19/00—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un complejo de metal mezclado de un compuesto de la Fórmula I, o una sal del mismo, en donde los metales mezclados comprenden un metal de transición del Grupo III-XII y un metal del Grupo II: (Fórmula I) (I) en donde X, R1, R2, R3 y R4 son como se definen en la presente, se produce en una cristalización de una etapa a partir de una solución del metal de transición del Grupo III-XII, el metal del Grupo II y un compuesto de la Fórmula I. Métodos para tratamiento de una condición patológica en un paciente, por ejemplo, una condición patológica causada por la presencia de radicales libres derivados de oxígeno, comprenden la administración del complejo de metal mezclado al paciente.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261583377P | 2012-01-05 | 2012-01-05 | |
| US201261656178P | 2012-06-06 | 2012-06-06 | |
| US201261668679P | 2012-07-06 | 2012-07-06 | |
| US201261721575P | 2012-11-02 | 2012-11-02 | |
| PCT/IB2012/056959 WO2013102806A1 (en) | 2012-01-05 | 2012-12-04 | Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014008247A true MX2014008247A (es) | 2015-03-09 |
Family
ID=47559596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014008247A MX2014008247A (es) | 2012-01-05 | 2012-12-04 | Calmangafodipir, una nueva entidad quimica, y otros complejos de metal mezclados, metodos de preparacion, composiciones y metodos de tratamiento. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US9187509B2 (es) |
| EP (1) | EP2800755B1 (es) |
| JP (2) | JP6131271B2 (es) |
| KR (1) | KR102086022B1 (es) |
| CN (2) | CN104169291B (es) |
| AU (1) | AU2012364227B2 (es) |
| BR (1) | BR112014016497B1 (es) |
| CA (1) | CA2862736C (es) |
| ES (1) | ES2683038T3 (es) |
| HK (1) | HK1245276B (es) |
| IN (1) | IN2014MN01495A (es) |
| MX (1) | MX2014008247A (es) |
| RU (2) | RU2622646C2 (es) |
| WO (1) | WO2013102806A1 (es) |
| ZA (1) | ZA201404904B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104169291B (zh) * | 2012-01-05 | 2017-08-15 | 普莱制药公司 | 新化学实体钙锰福地吡和其他混合金属配合物、制备方法、组合物以及治疗方法 |
| BR112015009963A2 (pt) * | 2012-11-02 | 2017-07-11 | Pledpharma Ab | uso de compostos para a preparação de composições farmacêuticas para o tratamento de câncer |
| US10233205B2 (en) | 2015-08-07 | 2019-03-19 | Auburn University | Magnetic resonance imaging contrast agent capable of detecting hydrogen peroxide and reducing reactive oxygen species |
| US11260060B2 (en) | 2016-01-11 | 2022-03-01 | Egetis Therapeutics Ab | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions |
| CN110139673B (zh) * | 2016-11-14 | 2022-03-22 | 卡尔森图纳投资公司 | 使用非过渡金属配位的二吡哆基化合物以预防和治疗化疗诱发的psn |
| US20240261375A1 (en) | 2021-05-18 | 2024-08-08 | Ltt Bio-Pharma Co., Ltd. | Pharmaceutical composition for treating or preventing disorder associated with administration of anticancer agent |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5091169A (en) | 1987-05-08 | 1992-02-25 | Salutar, Inc. | Dipyridoxyl phosphate NMRI contrast agent compositions |
| AR246956A1 (es) * | 1987-05-08 | 1994-10-31 | Salutar Inc | Compuesto quelante, un intermediario para preparar el mismo, y un procedimiento para preparar una composicion de medio de contraste. |
| US5223243A (en) | 1987-05-08 | 1993-06-29 | Salutar, Inc. | Dipyridoxyl phosphate chelating compound intermediates useful as NMRI contrast agents |
| US5403834A (en) | 1992-12-07 | 1995-04-04 | Eukarion, Inc. | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease |
| US6204259B1 (en) | 1993-01-14 | 2001-03-20 | Monsanto Company | Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
| GB9613182D0 (en) | 1996-06-24 | 1996-08-28 | Nycomed Imaging As | Method |
| GB9727224D0 (en) | 1997-12-23 | 1998-02-25 | Nycomed Imaging As | Method |
| JP2001527072A (ja) | 1997-12-23 | 2001-12-25 | ニユコメド・イメージング・アクシエセルカペト | 一酸化窒素を放出するキレート化剤およびその治療上の使用 |
| FR2823977B1 (fr) | 2001-04-26 | 2006-12-01 | Univ Rene Descartes | Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif |
| DE10359628A1 (de) | 2003-12-18 | 2005-07-21 | Oxeno Olefinchemie Gmbh | Katalysator und Verfahren zur Herstellung von 1-Olefinen aus 2-Hydroxyalkanen |
| US20070148154A1 (en) | 2004-12-17 | 2007-06-28 | Universite Rene Descartes (Paris V) | Use of superoxide dismutase mimetics and reductase gultatione in the form of anticancer drugs |
| WO2009078794A1 (en) | 2007-12-14 | 2009-06-25 | Pledpharma Ab | Compounds for use in the treatment of cancer |
| US8414866B2 (en) * | 2007-12-17 | 2013-04-09 | Ge Healthcare As | Method of magnetic resonance imaging of the heart with paramagnetic MN2+ |
| WO2011004325A1 (en) | 2009-07-06 | 2011-01-13 | Pledpharma Ab | Pharmaceutical compositions and therapeutic methods employing a combination of a manganese complex compound and a non-manganese complex form of the compound |
| CN104169291B (zh) * | 2012-01-05 | 2017-08-15 | 普莱制药公司 | 新化学实体钙锰福地吡和其他混合金属配合物、制备方法、组合物以及治疗方法 |
-
2012
- 2012-12-04 CN CN201280070691.1A patent/CN104169291B/zh active Active
- 2012-12-04 JP JP2014550770A patent/JP6131271B2/ja active Active
- 2012-12-04 BR BR112014016497-5A patent/BR112014016497B1/pt active IP Right Grant
- 2012-12-04 CN CN201710588057.1A patent/CN107353313B/zh active Active
- 2012-12-04 CA CA2862736A patent/CA2862736C/en active Active
- 2012-12-04 RU RU2014132184A patent/RU2622646C2/ru active
- 2012-12-04 MX MX2014008247A patent/MX2014008247A/es active IP Right Grant
- 2012-12-04 ES ES12815799.7T patent/ES2683038T3/es active Active
- 2012-12-04 WO PCT/IB2012/056959 patent/WO2013102806A1/en not_active Ceased
- 2012-12-04 IN IN1495MUN2014 patent/IN2014MN01495A/en unknown
- 2012-12-04 KR KR1020147021727A patent/KR102086022B1/ko not_active Expired - Fee Related
- 2012-12-04 EP EP12815799.7A patent/EP2800755B1/en active Active
- 2012-12-04 US US14/369,153 patent/US9187509B2/en active Active
- 2012-12-04 AU AU2012364227A patent/AU2012364227B2/en active Active
- 2012-12-04 RU RU2017119660A patent/RU2765805C2/ru active
-
2014
- 2014-07-02 ZA ZA2014/04904A patent/ZA201404904B/en unknown
-
2015
- 2015-10-26 US US14/922,555 patent/US9597334B2/en active Active
-
2017
- 2017-02-28 US US15/445,588 patent/US10111893B2/en active Active
- 2017-04-17 JP JP2017081176A patent/JP6316479B2/ja active Active
-
2018
- 2018-04-04 HK HK18104469.4A patent/HK1245276B/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2014000122A1 (en) | 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases | |
| JOP20210064A1 (ar) | عملية لتحضير 5- فلورو-1h- بيرازولوبيريدينات مستبدلة | |
| PH12014502524A1 (en) | Carboxylic acid compounds | |
| NZ715747A (en) | Syk inhibitors | |
| PH12013502549B1 (en) | Fused benzoxazepinones as ion channel modulators | |
| MD20140072A2 (ro) | Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin | |
| MD20160078A2 (ro) | Inhibitori ai Syk | |
| MY176814A (en) | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | |
| JO3453B1 (ar) | مشتقات البنزاميد لتثبيط نشاط abl1 و abl2 و bcr-abl1 | |
| MX2014008247A (es) | Calmangafodipir, una nueva entidad quimica, y otros complejos de metal mezclados, metodos de preparacion, composiciones y metodos de tratamiento. | |
| EA023204B9 (ru) | Производные гетероарилпиперидинов и -пиперазинов в качестве фунгицидов | |
| PH12015501316A1 (en) | Heterocyclic compound | |
| MD20140073A2 (en) | New phosphate compounds, a process for their preparation and pharmaceutical compositions containing them | |
| MY170262A (en) | Dicarboxylic acid compound | |
| MX349548B (es) | Compuestos de tienopirimidina. | |
| MX2016005993A (es) | Anfifilos biscationicos y triscationicos como agentes antimicrobianos. | |
| MX348979B (es) | Agente de control de enfermedades de las plantas. | |
| IN2014DN09314A (es) | ||
| UA116877C2 (uk) | Сполука з антибактеріальною і/абопротивірусною активністю | |
| TH149370A (th) | คาลมากาโฟดิเพอ, ตัวยาทางเคมีแบบใหม่, และสารประกอบเชิงซ้อนของโลหะผสมอื่นๆ, วิธีการของการเตรียม, องค์ประกอบ, และวิธีการของการรักษา (Calmangafodipir, a New Chemical Entity, and Other Mixed Metal Complexes, Methods of Preparation, Compositions, and Methods of Treatment) | |
| JO2948B1 (en) | New dihydro-oxazole openzo-2-azipenone compounds, their preparation and pharmaceutical compounds | |
| UA103796C2 (ru) | Способ получения разнометаллических комплексов ванадия |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| HC | Change of company name or juridical status |
Owner name: ACERUS BIOPHARMA INC. |